Trial Profile
Pharmacokinetics, pharmacodynamics and pharmacogenetics study of eribulin mesylate in patients with unresectable advanced or recurrent breast cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics
- 11 Sep 2013 New trial record